Bacillus Calmette-Guérin (BCG) shortages and the fragile BCG supply chain have created a bladder cancer treatment vacuum.
The FDA has expanded the approval of Winrevair to include treatment of adults with PAH WHO Group 1 to improve exercise capacity and WHO FC, and reduce the risk of clinical worsening events including ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback